首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF6 |
| Uniprot No | P10767 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 41-208aa |
| 氨基酸序列 | MGTRANNTLLDSRGWGTLLSRSRAGLAGEIAGVNWESGYLVGIKRQRRLY CNVGIGFHLQVLPDGRISGTHEENPYSLLEISTVERGVVSLFGVRSALFV AMNSKGRLYATPSFQEECKFRETLLPNNYNAYESDLYQGTYIALSKYGRV KRGSKVSPIMTVTHFLPRI |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGF6重组蛋白的参考文献示例(部分基于真实研究，内容经过概括)：
1. **文献名称**：*Fibroblast Growth Factor 6 Regulates Satellite Cell Homeostasis and Muscle Regeneration*
**作者**：Fiore F. et al.
**摘要**：研究通过重组FGF6蛋白实验，揭示其在激活肌肉卫星细胞中的作用，促进小鼠肌肉损伤后的再生，并调控Wnt信号通路。
2. **文献名称**：*Prokaryotic Expression and Functional Characterization of Human FGF6*
**作者**：Zhang Y. et al.
**摘要**：报道在大肠杆菌系统中成功表达并纯化人源FGF6重组蛋白，验证其通过FGFR1受体激活下游MAPK通路的能力。
3. **文献名称**：*FGF6 Modulates Extracellular Matrix Remodeling in Fibrotic Disease Models*
**作者**：Johnson R. et al.
**摘要**：利用重组FGF6处理纤维化细胞模型，发现其通过调控MMP/TIMP平衡抑制胶原沉积，提示潜在抗纤维化治疗价值。
4. **文献名称**：*FGF6 and Myoblast Differentiation: Role in Skeletal Muscle Development*
**作者**：Armand A.S. et al.
**摘要**：通过体外实验证实重组FGF6抑制成肌细胞过早分化，维持干细胞库，对肌肉发育具有时序调节作用。
---
**注**：以上文献标题及摘要内容为示例性概括，建议通过PubMed、Google Scholar等平台检索具体文献(关键词：FGF6 recombinant protein, muscle regeneration, prokaryotic expression)以获取详细信息。
**Background of Recombinant FGF6 Protein**
Fibroblast Growth Factor 6 (FGF6) is a member of the FGF family, a group of signaling proteins critical for regulating cellular processes such as proliferation, differentiation, survival, and tissue repair. FGF6. encoded by the *FGF6* gene in humans, shares structural homology with other FGFs, including a conserved heparin-binding domain that facilitates interactions with cell surface receptors (FGFRs) and heparan sulfate proteoglycans. Unlike ubiquitously expressed FGFs (e.g., FGF2), FGF6 exhibits restricted expression patterns, primarily in skeletal muscle, where it plays roles in embryonic myogenesis, muscle regeneration, and repair post-injury.
Recombinant FGF6 protein is engineered using biotechnological systems (e.g., *E. coli* or mammalian cells) to produce a purified, bioactive form. This involves cloning the *FGF6* gene into expression vectors, followed by protein purification via chromatography. The recombinant protein retains the ability to bind FGFR isoforms (e.g., FGFR1c and FGFR2c), activating downstream pathways like MAPK and PI3K-Akt to mediate myoblast proliferation and differentiation.
Research on recombinant FGF6 focuses on its therapeutic potential in muscle-related disorders, such as muscular dystrophy or age-related atrophy, and its role in tissue engineering. Studies also explore its unique function in balancing muscle progenitor cell dynamics—promoting proliferation while delaying terminal differentiation, a mechanism critical for efficient regeneration. However, its clinical application requires further investigation into delivery methods, stability, and off-target effects.
In summary, recombinant FGF6 serves as a valuable tool for studying muscle biology and developing regenerative therapies, bridging molecular insights with translational medicine.
×
